Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis

Pharmacological Reports

Volumn 65, Issue 3, 2013, Pages 624-631

  Tasset, Inmaculada ^a   Bahamonde, Carmen ^a   Agüera, Eduardo ^a   Conde, Cristina ^a   Cruz, Antonio H ^a   Pérez Herrera, Aleyda ^a,b   Gascón, Félix ^a   Giraldo, Ana I ^a   Ruiz, María C ^a   Lillo, Rafael ^a   Sánchez López, Fernando ^a   Túnez, Isaac ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adhesion molecules; Multiple sclerosis; Natalizumab; Nrf2; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MYELOPEROXIDASE; NATALIZUMAB; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD LEVEL; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MALE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIOXIDANTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; TRANSCRIPTION FACTORS;

EID: 84884495677     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71039-9     Document Type: Article

References (39)

1. Banning A, Brigelius-Flohe R: NF-kB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression. Antioxid Redox Signal, 2005, 7, 889-899. (Pubitemid 40967140)
2. Beristain-Pérez AS, Sánchez-Rodríguez MA, Ruiz-Ramos M, Mendoza-Núńez VB: Oxidative stress as a risk factor for development of diabetes mellitus, osteoarthritis and hypertension in elderly. Bioquimica, 2006, 31, 13-22.
3. Bielekova B, Becker BL: Monoclonal antibodies in MS: Mechanisms of action. Neurology, 2010, 74, S31-40.
4. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976, 72, 248-254.
5. Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH, Kunsch C: Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol, 2006, 290, H1862-1870.
6. Dringen R: Oxidative and antioxidative potential of brainmicroglial cells. Antioxid Redox Signal, 2005, 7, 1223-1233. (Pubitemid 41232519)
7. Flohe L, Gunzler WA: Assays of glutathione peroxidase. Methods Enzymol, 1984, 105, 114-121. (Pubitemid 14165378)
8. Garrabou G, Moren C, Lopez S, Tobias E, Cardellach F, Miro O, Casademont J: The effects of sepsis on mitochondria. J Infect Dis, 2012, 205, 392-400.
9. Ghabaee M, Jabedari B, Al EEN, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci, 2010, 120, 301-304.
10. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH: Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140, 918-934.
11. Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M, Olsson T et al.: Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol, 2011, 69, 83-89.
12. Gutierrez-Mariscal FM, Perez-Martinez P, Delgado-Lista J, Yubero-Serrano EM, Camargo A, Delgado-Casado N et al. Mediterranean diet supplemented with coenzyme Q10 induces postprandial changes in p53 in response to oxidative DNA damage in elderly subjects. Age, 2011, 34, 389-403.
13. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, Esterbauer H et al.: Oxidative damage in multiple sclerosis lesions. Brain, 2011, 134, 1914-1924.
14. Himadri P, Kumari SS, Chitharanjan M, Dhananjay S: Role of oxidative stress and inflammation in hypoxiainduced cerebral edema: A molecular approach. High Alt Med Biol, 2010, 11, 231-244.
15. Kaspar JW, Niture SK, Jaiswal AK: Nrf2:Inrf2 (keap1) signalling in oxidative stress. Free Radic Biol Med, 2009, 47, 1304-1309.
16. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 1983, 33, 1444-1452. (Pubitemid 14237132)
17. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW et al.: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol, 1990, 186, 464-478. (Pubitemid 20279989)
18. Luo S, Levine RL: Methionine in proteins defends against oxidative stress. FASEB J, 2009, 23, 464-472.
19. Miller N: Non vitamin plasma antioxidants. In: Free Radical and Antioxidant Protocols, Series: Methods in Molecular Biology. Ed. Amstrong D, Humana Press, New Jersey, 1998, 285-297.
20. Miller E, Mrowicka M, Malinowska K, Zolynski K, Kedziora J: Effects of the whole-body cryotherapy on a total antioxidative status and activities of some antioxidative enzymes in blood of patients with multiple sclerosispreliminary study. J Med Invest, 2010, 57, 168-173.
21. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Kunz B et al.: Natalizumab treatment reduces endothelial activity in ms patients. J Neuroimmunol, 2010, 227, 190-194.
22. Pare G, Ridker PM, Rose L, Barbalic M, Dupuis J, Dehghan A, Bis JC et al.: Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci. PLoS Genet, 2011, 7, e1001374.
23. Peng F, Yang Y, Liu J, Jiang Y, Zhu C, Deng X, Hu X et al.: Low antioxidant status of serum uric acid, bilirubin and albumin in patients with neuromyelitis optica. Eur J Neurol, 2011, 19, 277-283.
24. Pennisi G, Cornelius C, Cavallaro MM, Salinaro AT, Cambria MT, Pennisi M, Bella R et al.: Redox regulation of cellular stress response in multiple sclerosis. Biochem Pharmacol, 2011, 82, 1490-1499.
25. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol, 2005, 58, 840-846. (Pubitemid 41746873)
26. Price JA, Sanny CG, Shevlin D: Application of manual assessment of oxygen radical absorbent capacity (ORAC) for use in high throughput assay of "total" antioxidant activity of drugs and natural products. J Pharmacol Toxicol Methods, 2006, 54, 56-61. (Pubitemid 43975016)
27. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD et al.: Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci, 2010, 292, 28-35.
28. Sarada S, Himadri P, Mishra C, Geetali P, Ram MS, Ilavazhagan G: Role of oxidative stress and NFkB in hypoxia-induced pulmonary edema. Exp Biol Med, 2008, 233, 1088-1098.
29. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH: Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci, 2003, 23, 3394-3406. (Pubitemid 36531981)
30. Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H: The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism, 2000, 49, 1030-1035. (Pubitemid 30641441)
31. Sun XF, Zhang H: NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol, 2007, 22, 1387-1398. (Pubitemid 47470331)
32. Tasset I, Agüera E, Sánchez-López F, Feijóo M, Giraldo AI, Cruz AH, Gascón F, Túnez I: Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem, 2012, 45, 440-444.
33. Tasset I, Agüera E, Gascón F, Giraldo AI, Salcedo M, Cruz AH, Sánchez F, Túnez I: Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis (Spanish). Rev Neurol, 2012, 54, 449-452.
34. Tasset I, Perez-De La Cruz V, Elinos-Calderon D, Carrillo-Mora P, Gonzalez-Herrera IG, Luna-Lopez A, Konigsberg M et al.: Protective effect of tertbutylhydroquinone on the quinolinic-acid-induced toxicity in rat striatal slices: Role of the Nrf2-antioxidant response element pathway. Neurosignals, 2010, 18, 24-31.
35. Trebst C, Voss E, Skripuletz T, Stangel M: Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis. Curr Med Chem, 2010, 17, 640-650.
36. Trinanes J, Salido E, Fernandez J, Rufino M, Gonzalez-Posada JM, Torres A, Hernandez D: Type 1 diabetes increases the expression of proinflammatory cytokines and adhesion molecules in the artery wall of candidate patients for kidney transplantation. Diabetes Care, 2012, 35, 427-433.
37. Túnez I, Sánchez-López, Agüera E, Fernández-Bolańos R, Sánchez FM, Tasset I: Important role of oxidative stress biomarkers in Huntingon's disease. J Med Chem, 2011, 54, 5602-5606.
38. van Horssen J, Witte ME, Schreibelt G, de Vries HE: Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta, 2011, 1812, 141-150.
39. Witherick J, Wilkins A, Scolding N, Kemp K: Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis, 2010, 2011, 164608.